Andere talen Bristol-Myers Squibb Company Börse Stuttgart

Aandelen

BRM

US1101221083

Beurs gesloten - Börse Stuttgart Andere beurzen 19:19:46 18-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
37,66 ^EUR	-1,22%		-2,84%	-18,11%

18/06	Bristol Myers Squibb benoemt Michael R. McMullen tot Onafhankelijk Bestuurder en Lid van het Auditcomité, met ingang van 1 juli 2024	CI
18/06	Immunocore randomiseert eerste patiënt in fase 3-studie van combinatiebehandeling voor huidmelanoom	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	18/06
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	18/06
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	18/06
Bristol Myers : dividendes décidés par le conseil	18/06
Bristol Myers Squibb Announces Dividend	18/06
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	18/06
Bristol Myers : approbation de la FDA pour un traitement	14/06
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	13/06
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	13/06
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13/06
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13/06
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12/06
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12/06
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12/06
Evotec erhält Forschungszahlung von 20 Mio USD von Myers Squibb	12/06
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10/06
Geron shares surge after U.S. FDA approves blood disorder drug	07/06
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma	05/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Bristol-Myers CEO zegt dat het bedrijf in overgang is

09 januari 2024 om 19:06 uur